theMednetRegister

Medical Oncology

Head and Neck Cancers   

Questions discussed in this category

What is the recommended approach for systemic therapy for patients with locally recurrent p16-positive SCC of the oral cavity who are not candidates for resection or re-irradiation?
What would be the optimal choice of chemotherapeutic agents and duration?
2 Answers available
How do you treat SNUC?
Do you prefer upfront cisplatin/etoposide for 2 cycles, then 50 Gy with ENI, then resection, or induction chemo followed by definitive chemoradiation?...
5 Answers available
How do you approach a young patient with metastatic poorly differentiated thyroid cancer with rhabdoid/non-anaplastic features?
4 Answers available
When would you consider larynx preservation in patients with T4N+ SCC of the larynx?
2 Answers available
What is your experience with Gelclair for oral mucositis during head & neck radiotherapy?
1 Answer available
In what cases of T3N0 glottic SCC, would you omit chemotherapy and offer radiation alone?
3 Answers available
How should you approach treating curable laryngeal cancer with chemo-RT in a patient who had a myocardial infarction during treatment and requires CABG, given the cardiotoxicity of cisplatin and 5FU/carboplatin?
4 Answers available
How would you approach patients with high risk mucoepidermoid carcinoma (high grade) of the parotid gland for optimal adjuvant treatment?
5 Answers available
Would you prescribe TKIs for Stage IV differentiated thyroid cancer patients who are RAI-naive, with preserved performance status, and are not eligible for surgery?
2 Answers available
In what clinical situations do you order NavDx?
How do the results affect your recommendations for workup and management?
5 Answers available
What changes do you make in the management of non-endemic nasopharynx cancer compared to endemic?
For example, do you favor using different induction chemotherapy (gemcitabine/cisplatin or TPF) for endemic vs non-endemic disease? Do you favor usin...
2 Answers available
Would you recommend lymph node biopsy in a patient with SCC of the right ventral tongue (~1 cm) post excision with close margins and no noted adenopathy on imaging?
1 Answer available
Is it appropriate to dose de-escalate in low risk HPV+ SCC of the oropharynx outside of a clinical trial setting?
Such as those meeting the eligibility criteria for NRG HN002, <10 pack years, HPV+ T1-2N1-2b, T3N0-N2b
9 Answers available
How do you consider the role of probiotics for mucositis mitigation in patients receiving head and neck radiotherapy?
In light of the 4/2024 JCO publication by Peng et al., PMID 38215354
1 Answer available
Would you offer adjuvant immunotherapy after salvage neck dissection for persistent nodal disease after definitive chemoRT for a patient with p16+ oropharyngeal SCC?
1 Answer available
Do you typically recommend avoiding neupogen during radiation treatments?
6 Answers available
In what scenario would you recommend induction chemotherapy prior to chemo-radiation in head and neck cancers and what would be the preferred regimen?
4 Answers available
How do you counsel patients and partners of patients with HPV+ cancers regarding the HPV vaccine?
This would apply to gynecologic and GI cancers as well. And as long as the patient's partner is within the recommend age of <45 yo
1 Answer available
What are magic mouthwash alternatives that you would recommend?
There was a recall on viscous lidocaine and many of our patients cannot find it. What would you recommend as alternatives?
9 Answers available
When would you offer post-operative concurrent chemoradiation in anaplastic thyroid cancer?
Would you consider it for a patient with good PS but with limited metastatic disease? What dose fractionation would you prefer?
1 Answer available
How do you manage the thickened secretions secondary to xerostomia during head and neck radiation?
7 Answers available
What criteria do you use to determine the resectability of mucosal melanoma of the H&N region?
Is T4 disease a contraindication?
1 Answer available
How do you approach cisplatin ineligible patients with bulky EBER positive nasopharyngeal SCC for induction chemotherapy?
2 Answers available
Any role for adjuvant systemic therapy for resected sebaceous skin carcinoma?
1 Answer available
How do you approach patients with SMARCB1 deficient sinonasal carcinoma for immunotherapy?
1 Answer available
What is your approach to counseling patients who require definitive radiation therapy to the head and neck but for whatever reason, cannot/will not undergo recommended extractions?
Do anticipated fields affect whether extractions are required i.e., limited field glottic larynx could forego?
2 Answers available
How do you counsel patients regarding timing of dentures after definitive/post-operative H&N radiation with pre-treament tooth extractions?
4 Answers available
How do you approach patients with metastatic SCC of the larynx, PD-L1 <1, unable to tolerate 5-FU based chemotherapy due to grade 4 esophagitis/mucositis?
2 Answers available
How do you approach patients with locally advanced nasopharyngeal squamous cell carcinoma post induction chemotherapy with gemcitabine/cisplatin and imaging showing mild progression?
Can cisplatin be used again with chemo-radiation? 
2 Answers available
Is there a role for induction chemotherapy for locally advanced head and neck squamous cell carcinoma prior to definitive chemoradiation?
If you recommend or use induction chemotherapy, what is your preferred chemotherapy regimen?
1 Answer available
How do you approach patients with severe mucositis receiving chemo-radiation for head and neck cancer with regards to empiric antifungal or antiviral treatment?
Severe lymphopenia can develop during treatment and increase the risk of Candida/HSV superinfection, along with potential challenges for any procedure...
3 Answers available
How do you approach patients with recurrent papillary thyroid cancer following thyroidectomy who now has palpable cervical nodes and underwent neck dissection and RAI?
1 Answer available
In a patient with very advanced head and neck cancer treated with induction chemotherapy and then definitive radiation do you recommend adding concurrent chemotherapy with the radiation?
After initial induction chemo, how do you choose between radiation alone or concurrent CRT?
2 Answers available
How do you approach patients with node positive sebaceous cell carcinoma of the eyelid for adjuvant chemotherapy and radiation?
1 Answer available
How would you approach new dermal mets in a patient who recently finished chemoradiation for head and neck SCC?
2 Answers available
In a patient with history of successfully treated locally advanced H&N cancer, how do you discern between a metachronous second primary locally advanced lung SCC vs. metastatic head and neck SCC?
What clinical or radiographic factors would lean you in either direction - ie. time since index diagnosis, distribution or appearance of lung and noda...
5 Answers available
What is your approach to treat metastatic poorly differentiated thyroid cancer with papillary features?
Is there any role for RAI?
1 Answer available
Do you consider prior use of cisplatin for a previously diagnosed cancer a contraindication for its use as radiosensitizer in a new head & neck cancer?
What precautions, if any, should be instituted with the prior cisplatin exposure?
1 Answer available
In patients with nasopharyngeal SCC that have an excellent response to induction chemo, do you alter your chemo-RT dose/volumes in any way?
For example, initial imaging shows numerous bilateral nodal mets extending into the low neck but after induction gem/cis, originally involved nodes ar...
4 Answers available
With the current cisplatin and carboplatin shortages, for HPV+ H&N patients with indications for concurrent chemoRT, which agent do you recommend next?
If using cetuximab, would you recommend accelerated fractionation?
3 Answers available
What are best practices for oncologists during the national platinum shortage?
Please specify how your institution is allocating resources now or will be soon.
13 Answers available
How are you managing patients with H&N cancers meriting definitive concurrent chemoRT during cisplatin shortages?
Are you waiting until drug availability or changing to a preferred non-cisplatin radiosensitizer? If you're utilizing an alternative to cisplatin, wha...
3 Answers available
Would you offer a 2nd generation anti-AR or abiraterone after progression on ADT in patients with metastatic AR+, HER2 expressing salivary gland carcinoma?
How would you recommend proceeding if there are no other actionable variants on NGS? 
1 Answer available
What are your recommendations regarding sexual activity for a couple when one of them is diagnosed with a HPV-positive oropharyngeal cancer?
1 Answer available
How, if at all, does your approach to adjuvant chemoradiation differ with proton beam radiation vs. conventional photon radiation for H&N Cancers?
Is there data on efficacy or toxicity when chemotherapy is added to Proton beam therapy for head and neck cancer like there is data to support adding ...
3 Answers available
Do you omit adjuvant radiotherapy in T4a laryngeal SCC with favorable prognostic factors?
According to the NCCN guidelines, there is a highly selected group of T4a glottic larynx patients that can undergo observation instead of postoperativ...
4 Answers available
How do you balance aspiration risks with encouraging PO intake for HN cancer patients during and after chemoradiation?
Encouraging aggressive PO intake in patients with swallowing dysfunction may place them at risk for aspiration pneumonia, especially risky if undergoi...
1 Answer available
For cisplatin ineligible patients with locally advanced head and neck cancer, would you consider RT + immunotherapy rather than RT + cetuximab?
In light of recent trials showing no difference in outcomes with RT+cetuximab vs RT+IO, does this potentially lead us to use immunotherapy in cisplati...
1 Answer available
What methods do you use to prophylactically reduce radiation dermatitis for head and neck irradiation?
4 Answers available
Is oral lichen planus a contraindication for immunotherapy in a patient with recurrent oral SCC?
There have been reports of pembrolizumab leading to lichen planus (my understanding is lichen planus pathophysiology unclear, but potentially autoimmu...
1 Answer available
In what situations would you place a prophylactic trach prior to radiation for head and neck cancers?
1 Answer available
Is day 43 cisplatin 100mg/m2 needed after completion of RT in case of a delay related to neutropenia for locally advanced head and neck cancer?
Should the dose still be given after completion of RT?
2 Answers available
Do you routinely use mannitol to prevent cisplatin-induced nephrotoxicity?
If so, do you use it for all patients or only cisplatin doses >= 70 mg/m2? What dose of mannitol do you use?
4 Answers available
What criteria does your institution use to indicate patient is ready for PEG tube removal?
3 Answers available
What are your top takeaways in Head & Neck Cancers from ASCO 2022?
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice...
2 Answers available
Do you routinely offer doxycycline or minocycline prophylaxis for cutaneous reactions to EGFR inhibitors such as cetuximab?
If you do not use prophylaxis, what skin care strategy do you employ?
1 Answer available
Would you offer adjuvant capecitabine in a patient with nasopharyngeal carcinoma who has had cisplatin - gemcitabine induction followed by chemoradiotherapy with cisplatin?
Stage is cT4N2M0.
1 Answer available
How would you approach a patient with well controlled metastatic lung cancer who develops a new primary P16 positive oropharyngeal squamous cell carcinoma?
Is it reasonable to dose de-escalate since survival will likely depend on the metastatic lung cancer?
3 Answers available
Would you offer a RET inhibitor for a RET-mutated medullary thyroid carcinoma after R1 resection in a patient with elevated calcitonin?
What factors may favor RET inhibition versus observation?
1 Answer available
Would you recommend adding Debio 1143 to high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck?
Based on the results of the phase 2GORTEC study reference; Sun et al., PMID 32758455.
1 Answer available
Are there scenarios in which you would add nimotuzumab to cisplatin based concurrent chemoRT to treat locally advanced head and neck cancer?
1 Answer available
Would differentiating between embryonal vs alveolar rhabdomyosarcoma of the nasal cavity change your neoadjuvant chemotherapy regimen or make you consider neoadjuvant radiation in a locally advanced pleomorphic RMS?
40 yo adult patient with a~6cm mass with concern for skull base bony involvement (group III and stage III, no nodal involvement )
1 Answer available
What would you offer postoperatively for a pt with resected 3 separate HPV+ SCC primaries with pN1 disease with ECE who is cisplatin ineligible?
Resected small bilateral tonsil SCC & base of tongue SCC. The patient received 6 cycles of BEP 30 years ago for testicular cancer, and suffers fr...
1 Answer available
What is your approach to prescribing gabapentin for oral mucositis prophylaxis during chemoradiation?
Has your practice changed based on the randomized, phase 3 study showing prophylactic gabapentin is not effective? Please share your thoughts and exp...
3 Answers available
Does HPV-status play a role in selection of immune checkpoint inhibitors in upfront treatment of metastatic head and neck cancer?
How do HPV-positive patients respond to ICI compared to HPV-negative in your experience?
2 Answers available
In which oropharynx patients would you recommend TORS vs upfront RT or chemo-RT?
What clinical criteria would make you prefer TORS as the initial treatment approach?  
5 Answers available
Would you recommend the addition of chemotherapy in a patient with locally recurrent, unresectable squamous cell carcinoma of the head and neck for whom repeat radiation is planned?
Patient received full dose concurrent cis + RT previously.
2 Answers available
How do you approach staging and treatment for a p16+ nasopharyngeal SCC?
How do you stage? Like nasopharynx or p16+ oropharynx? Do you treat it like npx ca with chemo xrt + adj chemo or like opx p16+ with definitive chemo ...
2 Answers available
How do you manage anaplastic thyroid cancer that is progressing through radiation therapy?
2 Answers available
Assuming a clinical trial is unavailable, would you consider tazemetostat in a patient with metastatic INI1/SMARCB1 deficient sinonasal carcinoma?
Has anyone tried this approach with success?
1 Answer available
Would you offer adjuvant chemoRT to a patient who underwent neck dissection for a T0N1M0, p16+ head and neck squamous cell carcinoma?
Lymph node is 4.5cm with no reported ECE. Does the size of the LN or presence or absence of ECE affect your decision?
1 Answer available
How would you approach synchronous early stage NSCLC adenocarcinoma and locally advanced symptomatic squamous head and neck cancer that is deemed nonresectable upfront?
Would you prioritize the head and neck cancer or treat the lung cancer first with SBRT to take care of it first? How about if there is mediastinal inv...
1 Answer available
What is your preferred approach to adjuvant therapy for a Masaoka Stage III thymic carcinoma after R1 resection?
Would you elect for concurrent chemoRT or RT alone?
1 Answer available
Would you recommend induction chemotherapy such as TPF to a patient with locally advanced sarcomatoid carcinoma of the nasal cavity?
Or would you recommend upfront resection as long as borderline resectable?
1 Answer available
Are there any circumstances in which you would recommend adjuvant chemoradiation for resected olfactory neuroblastoma?
4 Answers available
Is it safe to deliver SBRT with concurrent immunotherapy to head and neck sites of progressive metastatic disease?
What doses and constraints do you use?
1 Answer available
Are there any preferred chemotherapy regimens for Stage IV NUT carcinoma?
Is there any role of radiation therapy for these patient for symptomatic relief? 
2 Answers available
What is your preferred treatment for locally advanced poorly differentiated carcinoma of the nasopharynx with bulky neck nodes that is EBER negative and p16 negative?
Would you consider induction: TPF vs cis/gem or would you proceed with chemoradiation with cis/RT and consider adjuvant cis/5FU?
3 Answers available
Do you offer adjuvant androgen deprivation therapy for AR+ salivary ductal carcinomas treated with curative intent?
If so, how do you sequence it? Would you consider before adjuvant radiation vs concurrent with adjuvant (chemo)radiation vs after adjuvant radiation? ...
1 Answer available
Is it essential to wait one week after loading dose of erbitux to start RT for head and neck cancer?
In the post-op setting, would you delay 1 week even if it took them out of the 6 weeks post-op window? Meaning the loading dose of erbitux was given d...
1 Answer available
For a patient with H&N squamous cell carcinoma who underwent salvage neck dissection for residual disease following primary chemoradiation with weekly cisplatin, do you offer any adjuvant therapy thereafter if extranodal extension is found?
In primary surgical resection, ENE on surgical path would be indication to add adjuvant chemoradiation. After progression through definitive chemoradi...
3 Answers available
How would you approach therapy for a nasal high grade neuroendocrine tumor with ipsilateral local cervical adenopathy?
2 Answers available
Is the COVID-19 pandemic affecting your choice of high dose versus weekly cisplatin for definitive concurrent chemoradiation for HPV negative head and neck cancer?
1 Answer available
How would you treat laryngeal neuroendocrine carcinoma?
If advanced stage do you follow same guidelines as Scc? Do you use same Cth regimen? Role of total laryngectomy ? 
1 Answer available
How would you approach patient with metastatic anaplastic thyroid cancer with NGS revealing only ARID1A mutation?
1 Answer available
When would you consider adjuvant chemoradiation in a patient with esthesioneuroblastoma?
Would gross ENE or R1 resection trigger you to consider adding chemo? If so, do you use weekly cisplatin or cisplatin/etoposide?
1 Answer available
Would you offer, and what data would support, the use of an FGFR inhibitor in FGFR3 mutated anaplastic thyroid cancer?
1 Answer available
What treatment would you initiate post-operatively for patients with de novo metastatic follicular thyroid CA requiring laminectomy for cord compression?
In addition to TSH suppression, would you opt for RAI, targeted treatment based off NGS, or lenvatinib?
1 Answer available
How will your management of head and neck cancers change with the COVID-19 pandemic?
Are you employing more or less primary chemoRT v. surgery for some cancers? Are you dose de-escalating? What are issues radiation oncologists should b...
6 Answers available
How would you approach therapy in a young adult with synovial sarcoma of the head and neck who is not amenable to surgery due to location on the face?
2 Answers available
What is your approach in deciding on definitive therapy for locally advanced, HPV-negative head and neck cancer unsuitable for standard cisplatin based chemo?
How do you decide on other chemo regimen? (Dosing, frequency, carboplatin based, non-platinum based etc.) Would you use Cetuximab? Altered fractiona...
4 Answers available
For patients with locally unresectable/metastatic head and neck cancer who achieve complete response to chemoimmunotherapy, how do you manage their subsequent care in terms of continuing therapy vs. close monitoring?
1 Answer available
For patients with p16+ SCC of a cervical lymph node subsequently found to have an oropharyngeal mass on imaging, is it necessary to biopsy the primary site prior to proceeding with definitive RT?
4 Answers available
Is it acceptable to give weekly cisplatin for patients with locally advanced head and neck SCC undergoing chemoradiation?
Is there data to support every 3 week dosage v. weekly? https://ascopost.com/news/march-2022/postoperative-weekly-vs-every-3-week-cisplatin-i...
3 Answers available
How do you treat a patient with synchronous locally advanced lung and head and neck cancers?
Does the availability of first line checkpoint inhibitor therapy affect your treatment decision? 
2 Answers available
How do you distinguish between radiation necrosis, abscess, or disease recurrence in head and neck cancer patients?
Do different modalities of imaging (PET vs MRI vs CT) help you to distinguish one etiology versus the others? What about other clinical characteristic...
1 Answer available
How do you manage chronic radiation laryngeal edema for patients treated with RT for a larynx primary in the past?
Aside from smoking cessation, what interventions have you found useful to manage patients with chronic symptomatic laryngeal edema? Steroids seem to b...
3 Answers available
Do you give two or three cycles of cisplatin to patients with H&N squamous cell carcinoma receiving chemoradiation with Q3 week cisplatin?
4 Answers available
Would you consider low dose lenvatinib or dabrafenib/trametinib for rapidly progressive RAI refractory thyroid cancer with BRAF V600E mutation in a patient in whom you are concerned about tolerance of full dose lenvatinib?
Such as in patients who are elderly or have borderline performance status
1 Answer available
How should you manage a coronavirus infected/suspected patient who is receiving radiotherapy and cannot interrupt or delay their cancer treatment?
How would you approach a patient who is receiving chemoRT but has confirmed COVID-19 with minor symptoms, as breaking treatment for 2 weeks quarantine...
7 Answers available
What cisplatin regimen do you prefer with adjuvant radiation in oropharyngeal SCC that is pT4N2 after surgery and bilateral neck dissection?
Is there data for weekly versus every 3 week cisplatin in this setting?
3 Answers available
Would you offer adjuvant TKI to patients with locally recurrent multifocal adenoid cystic carcinoma?
For example, for a patient that has been through multiple disfiguring surgeries and radiation and wants to delay time to next resection.
1 Answer available
What is your first line therapy for progressive symptomatic metastatic adenoid cystic carcinoma?
Do you start with TKIs or platinums?
2 Answers available
For concurrent chemoradiation in head and neck cancers, how important is the timing of weekly radiosensitizing cisplatin early versus late in the week?
Specifically with reference to rural settings where the logistics of early in the week delivery may be more challenging.
4 Answers available
How does the management of nasopharyngeal cancer in kids/young adults differ from adult patients?
-The data on induction for adult H&N ca has been mixed (excluded NPX) but recent data suggest a benefit for adult NPX. -Given that this is standa...
1 Answer available
Would you switch from weekly cetuximab to cisplatin during definitive chemoRT for locally advanced oropharyngeal SCC?
Patient initially was started on cetuximab due to renal insufficiency of unclear chronicity (uncontrolled hypertension) that significantly improved du...
0 Answers available
Do you always use platinum/5-FU as the chemo backbone with pembrolizumab for recurrent/metastatic H&N cancer?
Although platinum/5-FU was used in KEYNOTE-048, can an alternative like carbo/paclitaxel be given since it may be better tolerated?
3 Answers available
How would you manage a local recurrence at the skull base after concurrent chemoRT for locally advanced nasopharyngeal carcinoma?
Given not surgical candidate and within 1 year of chemoRT (recurrence within RT field), would you repeat chemoRT, RT alone, or systemic therapy alone?...
2 Answers available
Do you check baseline or surveillance audiometry (if not overtly symptomatic) to screen for hearing loss in all patients getting cisplatin?
3 Answers available
Do you offer induction chemotherapy for patients with cT4N0 laryngeal cancer who decline surgery and are not candidates for high dose cisplatin-based concurrent RT?
NCCN suggests either concurrent chemoRT or induction chemotherapy in these patients.
4 Answers available
How do you deal with worsening tinnitus in patients on concurrent chemoradiation with weekly cisplatin for head and neck cancer?
2 Answers available
In light of recent data from ASCO 2019 and the NEJM, would you recommend induction chemotherapy or an adjuvant approach in combination with chemoradiation for locally advanced nasopharyngeal carcinoma?
Does your approach differ by EBV status?  
1 Answer available
How soon after ChemoRT for a head and neck cancer can you safely initiate esophageal dilation?
3 Answers available
How would you treat a isolated, high grade neuroendocrine carcinoma of the neck with no obvious primary or systemic disease?
Would you recommend surgery, definitive chemoRT, or chemotherapy alone?
2 Answers available
For patients with metastatic radioctive iodine refractory papillary thyroid carcinoma that is BRAF V600E mutant and rapidly progressive, would you consider dabrafenib/trametinib combo instead of lenvantinib or sorafenib first line?
Aggressive histology with tall cell variant papillary thyroid carcinoma that's progressed 2 months after RAI and while on TSH suppression, without tra...
1 Answer available
What systemic therapy would you suggest for metastatic odontogenic clear cell carcinoma with no actionable mutations on NGS?
0 Answers available
Should upfront neck dissection in head and neck squamous cell carcinoma obviate the need for chemo in a T1N2 oropharyngeal cancer with no ECE?
Some ENTs advocate for a neck dissection as a way to avoid chemotherapy if there is a high chance there is no ECE. This is without removing the primar...
1 Answer available
When do you consider upfront surgery for locally advanced (T4) sinonasal CA?
Would you proceed with induction chemotherapy (eg TPF or cis/gem) to downstage or neoadjuvant chemoRT? Would your approach be different if there is or...
2 Answers available
How would you approach a locally advanced, radioiodine naive papillary thyroid carcinoma not amenable to a non-morbid surgery?
Have you seen RAI or lenvatinib be efficacious for locally advanced disease — allowing for better surgical outcomes?  Do you utilize EBRT?
3 Answers available
How would you manage contralateral neck recurrence <6 mos. following resection and adjuvant CCRT for node positive tongue cancer?
If neck dissection was done, do you offer adjuvant chemo and/or XRT?
1 Answer available
How do you approach your choice of systemic therapy for relapsed/metastatic H&N cancer (failed definitive concurrent chemoRT) not amenable to further locoregional therapies?
Do you have a time threshold for re-challenge with platinum?  Of note, Checkmate 141 defined platinum refractory as relapse within 6 months of pl...
1 Answer available
How do you time same-day chemotherapy and radiation for patients undergoing concurrent chemoRT?
For the first treatment day (during combined chemo/XRT courses), is it ok to give XRT first then send the patient for chemo or should the chemo be giv...
3 Answers available
If a stage I laryngeal cancer completely responds to FU-based chemotherapy (given for another malignancy) would you consider observation?
4 Answers available
What is your preferred radiation sensitizing regimen for cisplatin-ineligible patients with locally advanced unresectable p16+ tonsil SCCa?
1 Answer available
How stringent or flexible are you with concurrent chemotherapy and radiation starting on the same day in the definitive CRT setting for HN patients?
Do you ever start radiation +/- 24-48 hrs from C1D1 for chemotherapy due to logistical barriers? Do you prefer chemotherapy to start at beginning of ...
4 Answers available
How do you manage small oropharyngeal cancers with N1 or N2 disease?
Is concurrent chemotherapy necessary for these patients?
3 Answers available
How would you manage papillary variant squamous cell carcinoma of the oropharynx?
Does papillary histology influence your decisions regarding surgery, chemo, radiation dose or nodal coverage?
1 Answer available
When would you use concurrent cetuximab with radiation for a patient with H&N cancer who is not a good candidate for concurrent chemotherapy?
Routinely? Only with oropharyngeal cancer etc.? Given that low expression of EGFR subset did better, do you believe there is a true benefit in cetuxim...
2 Answers available
How would you approach distant oligometastatic HPV positive oropharyngeal cancer previously treated with definitive local therapy?
Would you offer locoregional control alone, locoregional with adjuvant therapy, or active surveillance?
1 Answer available
How would you treat recurrent parotid gland carcinoma with unresectable, metastatic disease?
1 Answer available
How would you treat a patient with head and neck squamous cell carcinoma and adverse features with borderline renal function in the adjuvant setting?
Which of the systemic options would you give concurrently with radiation therapy in the adjuvant setting? According to NCCN guidelines, high dose...
1 Answer available
Would you ever NOT recommend adding concurrent chemotherapy to adjuvant radiation in +ECE oropharynx SCC patients who can tolerate it?
In the context of the new staging systems and possible differences of HPV mediated vs smoking mediated oropharynx SCC, would you ever not recommend co...
2 Answers available
Do you prefer rhTSH for TSH stimulation instead of thyroid hormone withdrawal when treating patients with radioactive iodine for papillary thyroid carcinoma?
If not, what is your thyroid hormone withdrawal protocol?  If so, would you still treat a patient with possibly metastatic disease?  
1 Answer available
What strategies do you employ to mitigate mucositis related pain during the treatment of head and neck cancer?
5 Answers available
While we await the completion of RTOG 1008, what instances do you offer chemotherapy for salivary gland tumors?
1 Answer available
What is your preferred first-line regimen for metastatic head and neck cancer?
Do you typically use 5-FU/cisplatin/cetuximab, or do you prefer other options?
1 Answer available
Do you transfuse anemic head and neck cancer patients undergoing chemoradiation?
If so, when? Although anemia is associated with worse local control in HN cancer, I don't know of any data that shows that blood transfusions can help...
2 Answers available
How do you sequence systemic therapies for recurrent/metastatic head/neck cancer following the recent approval of pembrolizumab?
Do HPV and/or PD-L1 status influence your decision making? 
1 Answer available
How would you follow patients with differentiated thyroid cancer that no longer picks up iodine after thyroidectomy and RAI, and have thyroglobulin antibodies?
If a patient had a recurrence that was pathologically proven despite negative idodine scans, what imaging scans would you follow up with for surveilla...
1 Answer available
Is there data to suggest that definitive chemoradiation to 70Gy vs. postoperative chemoradiation to 60 or 66Gy has any different clinically significant effects on long term swallowing function and other side effects of H&N cancer treatment?
Our ENT surgeons often tell patients with evidence of matted nodes on imaging that their swallowing function will be much worse after 70Gy as compared...
1 Answer available
What is your approach for a locally advanced (stage IVA secondary to N2 disease in the neck), HPV-negative, squamous cell carcinoma of the base of tongue in a patient without significant comorbidities?
Definitive chemoradiation vs. surgery followed by adjuvant radiation/chemoradiation?
1 Answer available
What criteria do you use for induction chemotherapy in advanced head and neck cancers?
Even though we do not have the best data on the use of induction chemotherapy, what are current practices? Is your practice different between HPV+ an...
2 Answers available


Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-03-01
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-09-01
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
The Lancet. Oncology, 2013-03
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Cancer, 2004-03-15
Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma?
Mayo Clinic proceedings, 2012-03
Long-term functional and oncologic results of transoral robotic surgery for oropharyngeal squamous cell carcinoma.
Oral oncology, 2016-09
Transoral robotic surgery: The radiation oncologist's perspective.
Cancer, 2002-06-01
Squamous cell carcinoma of the oropharynx: surgery, radiation therapy, or both.
The Lancet. Oncology, 2010-01
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
Oral oncology, 2014-05
Refining risk stratification for locoregional failure after chemoradiotherapy in human papillomavirus-associated oropharyngeal cancer.
Head & neck, 2015-03
Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-04-20
Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-01-01
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Cancer, 2010-10-01
Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer.
Head & neck, 2016-04
Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review.
Cancer, 1990-11-01
Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Long-term results of the Radiation Therapy Oncology Group study 81-17.
Ann. Oncol., 2010 Apr 28
Concomitant chemoradiation versus radical radiotherapy in advanced squamous cell carcinoma of oropharynx and nasopharynx using weekly cisplatin: a phase II randomized trial.
J Clin Oncol, 2017 Dec 8
Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial.
Radiother Oncol, 2011-01-01
The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy--results from the randomized DAHANCA 5 study.
Acta Oncol, 2011-10-01
Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? - results from the randomized DAHANCA 5 and 7 trials.
Int J Radiat Oncol Biol Phys,
Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial.
Laryngoscope, 2016 Jun 12
Laryngeal chondrosarcoma: A systematic review of 592 cases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-01-15
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
N. Engl. J. Med., 2008-09-11
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
JAMA otolaryngology-- head & neck surgery, 2016-11-01
Association of Adjuvant Chemoradiotherapy vs Radiotherapy Alone With Survival in Patients With Resected Major Salivary Gland Carcinoma: Data From the National Cancer Data Base.
Pain practice : the official journal of World Institute of Pain, 2017-11
Methylene Blue for the Treatment of Intractable Pain Associated with Oral Mucositis.
Med Phys, 2013-08-01
The impacts of dental filling materials on RapidArc treatment planning and dose delivery: challenges and solution.
Int. J. Radiat. Oncol. Biol. Phys., 2009-01-01
Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the National Cancer Institute of Canada Clinical Trials Group (HN3).
N. Engl. J. Med., 2012-05-03
Strategies of radioiodine ablation in patients with low-risk thyroid cancer.
N. Engl. J. Med., 2012-05-03
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.
Cancer journal (Sudbury, Mass.), 2017
Role of Induction Chemotherapy Prior to Chemoradiation in Head and Neck Squamous Cell Cancer-Systematic Review and Meta-analysis.
Cancer, 2018-06-01
Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma.
International journal of radiation oncology, biology, physics, 2015-12-01
Phase 2 Trial of De-intensified Chemoradiation Therapy for Favorable-Risk Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-08-01
Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma.
J Clin Oncol, 2019 Aug 14
Phase II Trial of De-Intensified Chemoradiotherapy for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.
Lancet (London, England), 2019-01-05
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
J. Natl. Cancer Inst.,
Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma.
Radiother Oncol, 2009 May 14
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.
J Clin Oncol, 2021 Oct 26
Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).
J Clin Oncol, 2021 May 27
Treatment De-intensification for HPV-Positive Oropharynx Cancer: What Is Currently Acceptable?
Radiother Oncol, 2020 Feb 07
Randomized clinical trial on reduction of radiotherapy dose to the elective neck in head and neck squamous cell carcinoma; update of the long-term tumor outcome.
Head & neck, 2014-01
Aspiration pneumonia after chemo-intensity-modulated radiation therapy of oropharyngeal carcinoma and its clinical and dysphagia-related predictors.
Otolaryngol Head Neck Surg, 1994 Feb
Effects of postural change on aspiration in head and neck surgical patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-04-20
Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer.
Cancer,
Chemotherapy alone with curative intent in patients with invasive squamous cell carcinoma of the pharyngolarynx classified as T1-T4N0M0 complete clinical responders.
Head Neck, 2019 Feb 01
Ten-year outcome of curative "exclusive" chemotherapy in N0M0 squamous cell carcinoma of the larynx and pharynx with complete clinical response.
The New England journal of medicine, 2018-02-22
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Lancet, 2018 Nov 15
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
International journal of radiation oncology, biology, physics, 1994-06-15
Combined-modality therapy of esophageal cancer with radiotherapy, etanidazole, and cisplatin-fluorouracil, with or without surgery: neurotoxicity, other toxicities and outcome.
International journal of radiation oncology, biology, physics, 2010-12-01
Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010-06
Phase II trial of combined modality therapy with myeloid growth factor support in patients with locally advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands), 2021 Jan 30
Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial.
Int J Radiat Oncol Biol Phys,
Long-Term Results for MC1273, A Phase II Evaluation of De-Escalated Adjuvant Radiation Therapy for Human Papillomavirus Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC).
N. Engl. J. Med., 2019 May 31
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma.
The New England journal of medicine, 2015-02-12
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Oral oncology, 2017-06
Small cell carcinoma of the head and neck: An analysis of the National Cancer Database.
The New England journal of medicine, 2018-11-22
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
J. Clin. Oncol., 2019 Sep 25
Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study.
J Pharm Sci,
Pharmacokinetics of cisplatin and its monohydrated complex in humans.
J. Clin. Oncol.,
Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-06-20
Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma.
Int. J. Radiat. Oncol. Biol. Phys.,
A re-evaluation of split-course technique for squamous cell carcinoma of the head and neck.
Lancet, 2019 Nov 01
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-12-01
Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.
The Lancet. Oncology, 2017-09
Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis.
J Natl Compr Canc Netw,
Survival After Definitive Chemoradiotherapy With Concurrent Cisplatin or Carboplatin for Head and Neck Cancer.
Future Oncol, 2016 Aug 23
Definitive chemoradiotherapy for squamous head and neck cancer: cisplatin versus carboplatin? A meta-analysis.
The New England journal of medicine, 2006-02-09
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
Lancet Oncol., 2017 May 09
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Cancer discovery, 2015-07
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.
J Immunother Cancer,
alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy.
J Clin Oncol, 2021 Apr 26
Management of Salivary Gland Malignancy: ASCO Guideline.
Eur J Cancer, 2019 Feb 13
Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma.
Laryngoscope, 2014 Jul
Adjuvant stereotactic body radiotherapy±cetuximab following salvage surgery in previously irradiated head and neck cancer.
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2016-12
Drainage Patterns to Nontraditional Nodal Regions and Level IIB in Cutaneous Head and Neck Malignancy.
Head Neck,
Lymphatic drainage of the nasal fossae and nasopharynx: preliminary anatomical and radiological study with clinical implications.
The New England journal of medicine, 2007-10-25
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998-04
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
N Engl J Med,
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Int. J. Radiat. Oncol. Biol. Phys., 2011 Jun 15
Esthesioneuroblastoma: is there a need for elective neck treatment?
Cancer, 2004-12-01
Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-05-10
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.
The Lancet. Oncology, 2016-07
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
N Engl J Med, 2016 Oct 08
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Int J Radiat Oncol Biol Phys, 2021 Nov 20
Randomized Phase 3, Double-blind, Placebo-controlled Study of Prophylactic Gabapentin for the Reduction of Oral Mucositis Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-07-01
Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-06-01
Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results.
Head & neck, 2014-05
Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV-positive and HPV-negative locally advanced squamous cell carcinoma of the oropharynx.
Lancet Oncol, 2020 Aug 03
Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-03-10
Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.
Cancer chemotherapy and pharmacology, 2003-07
Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
J Oncol Pharm Pract, 2009 Sep 16
A comparison of the rates of cisplatin (cDDP)--induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventative measure.
Cancer Treat Rep,
Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study.
Ann Pharmacother, 2012 Jan 31
The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy.
Lancet, 2021 Jun 07
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.
International journal of radiation oncology, biology, physics, 2014-03-01
Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis.
N Engl J Med, 2020 Sep 18
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
BMC Cancer, 2021 May 27
Induction chemotherapy combined with immunotherapy in locally advanced head and neck squamous cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-08-10
Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2020 Sep 09
Sebaceous Carcinoma Epidemiology and Genetics: Emerging Concepts and Clinical Implications for Screening, Prevention, and Treatment.
Medicine (Baltimore), 2019 Dec
Randomized, self-controlled, prospective assessment of the efficacy of mometasone furoate local application in reducing acute radiation dermatitis in patients with head and neck squamous cell carcinomas.
J Clin Invest, 2013 Nov 15
Topical hypochlorite ameliorates NF-κB-mediated skin diseases in mice.
Nat Commun, 2022 Nov 16
Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors.
JAMA Otolaryngol Head Neck Surg, 2022 Dec 22
Osteoradionecrosis of the Jaw Following Proton Radiation Therapy for Patients With Head and Neck Cancer.
American journal of clinical oncology, 2005-12
Head and neck mucosal melanoma.
Head & neck, 2016-01
Update on primary head and neck mucosal melanoma.
The Laryngoscope, 1994-02
Mucosal melanoma of the head and neck: the impact of local control on survival.
Oral and maxillofacial surgery, 2023 Apr 05
Head and neck mucosal melanoma: radiological considerations and UK imaging guidelines.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-07-15
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
International journal of radiation oncology, biology, physics, 2000-04-01
The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck.
Lancet Oncol., 2012-02-01
Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial.
J Clin Oncol, 2004 Jan 1
Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma.
The Laryngoscope, 2017-10
Definitive chemoradiotherapy with carboplatin for squamous cell carcinoma of the head and neck.
In Vivo, 2022 Mar-Apr
Cisplatin Carboplatin and Paclitaxel in Radiochemotherapy for Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma.
J Clin Oncol, 2023 Jan 27
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation.
Eur J Cancer, 2007 Apr 27
Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial.
J Clin Oncol, 2018 Jun 07
Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial.
Journal of the National Cancer Institute, 2016-06
An Ethical Framework for Allocating Scarce Life-Saving Chemotherapy and Supportive Care Drugs for Childhood Cancer.
Pediatrics, 2014 Feb 02
Chemotherapy drug shortages in pediatric oncology: a consensus statement.
N. Engl. J. Med.,
Pembrolizumab for Early Triple-Negative Breast Cancer.
The Journal of urology, 2018-12
Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma.
N. Engl. J. Med.,
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
Lancet Oncol., 2014 Feb 18
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.
NEJM Evidence, 2022 Jun 1
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
Br J Cancer, 2014 Apr 15
Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.
Cancer, 2011-06-15
Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial.
Eur J Cancer, 2017 Nov 28
Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.
N. Engl. J. Med., 2019 Sep 28
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Lancet Oncol, 2021 Jan 18
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
J Clin Oncol, 2021 Apr 19
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.
J Clin Oncol, 2003 Jul 01
Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group.
JAMA, 2019 Apr 16
Effect of Doxepin Mouthwash or Diphenhydramine-Lidocaine-Antacid Mouthwash vs Placebo on Radiotherapy-Related Oral Mucositis Pain: The Alliance A221304 Randomized Clinical Trial.
Head Neck, 2016 Mar 29
Effectiveness of honey on radiation-induced oral mucositis, time to mucositis, weight loss, and treatment interruptions among patients with head and neck malignancies: A meta-analysis and systematic review of literature.
The Lancet. Oncology, 2017-05
Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.
Adv Radiat Oncol, 2022 May 18
Evolutionary Action Score of Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234.
Oral Oncol, 2022 May 27
Long term toxicity and tolerance of concurrent docetaxel with radiotherapy in cisplatin-ineligible head and neck cancer patients.
Radiother Oncol, 2017 Aug 29
Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial.
Lancet Oncol,
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020 Feb 04
Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2021 Jan 27
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.
Annals of oncology : official journal of the European Society for Medical Oncology, 2013 Nov 19
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Journal of the National Cancer Institute, 2009 Jan 27
Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy.
Journal of the National Cancer Institute, 2009 Mar 24
Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013-11
Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients.
Cancer, 2002-11-15
Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma.
Journal of experimental therapeutics & oncology, 1996-03
Prevention of mucositis in irradiated head and neck cancer patients.
Indian J Palliat Care, 2009 Jul
Radiation induced oral mucositis.
La Radiologia medica, 1996 Apr
[Can the prophylactic treatment of mycotic mucositis improve the time of performing radiotherapy in head and neck tumors?].
QJM : monthly journal of the Association of Physicians, 2020 Jan 01
Effects of early nutritional intervention on oral mucositis in patients with radiotherapy for head and neck cancer.
Integrative cancer therapies, 2021 Jan-Dec
Chinese Herbal Medicine to Reduce Radiation-Induced Oral Mucositis in Head and Neck Cancer Patients: Evidence From Population-Based Health Claims.
Indian journal of dental research : official publication of Indian Society for Dental Research, 2020 Sep-Oct
Effectiveness of curcumin mouthwash on radiation-induced oral mucositis among head and neck cancer patients: A triple-blind, pilot randomised controlled trial.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2021 Jul 31
A randomized, controlled phase II trial of maxillofacial and oral massage in attenuating severe radiotherapy-induced oral mucositis and lipid metabolite changes in nasopharyngeal carcinoma.
Evidence-based complementary and alternative medicine : eCAM, 2022 Apr 19
Efficacy of the Nourishing Yin and Clearing Heat Therapy Based on Traditional Chinese Medicine in the Prevention and Treatment of Radiotherapy-Induced Oral Mucositis in Nasopharyngeal Carcinomas: A Systematic Review and Meta-Analysis of Thirty Randomized Controlled Trials.
The Journal of laryngology and otology, 2008 May 19
Honey as topical prophylaxis against radiochemotherapy-induced mucositis in head and neck cancer.
The journal of contemporary dental practice, 2008 Mar 01
The effect of topical application of pure honey on radiation-induced mucositis: a randomized clinical trial.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020 Sep 05
A systematic review of interventions to mitigate radiotherapy-induced oral mucositis in head and neck cancer patients.
International journal of radiation oncology, biology, physics, 2005 Oct 24
Tetracaine oral gel in patients treated with radiotherapy for head-and-neck cancer: final results of a phase II study.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2023 Sep 01
Accounting for fractionation and heterogeneous dose distributions in the modelling of osteoradionecrosis in oropharyngeal carcinoma treatment.
The American journal of surgical pathology, 2017-04
SMARCB1 (INI-1)-deficient Sinonasal Carcinoma: A Series of 39 Cases Expanding the Morphologic and Clinicopathologic Spectrum of a Recently Described Entity.
World journal of clinical cases, 2023 Nov 16
Immunotherapy in SMARCB1 (INI-1)-deficient sinonasal carcinoma: Two case reports.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2020 Jul 14
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.
Oral oncology, 2013 Jan 29
A phase II study of induction carboplatin and gemcitabine followed by chemoradiotherapy for the treatment of locally advanced nasopharyngeal carcinoma.
American journal of clinical oncology, 2007-04
Prognostic significance of paraglottic space invasion in T2N0 glottic carcinoma.
N Engl J Med, 2015 Aug 6
Elective versus Therapeutic Neck Dissection in Node-Negative Oral Cancer.
Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery, 2023 Oct 20
Meta-analysis of multi-modality therapies in sinonasal undifferentiated carcinoma-A timely update.
The New England journal of medicine, 1991-06-13
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-02-20
Induction Chemotherapy Response as a Guide for Treatment Optimization in Sinonasal Undifferentiated Carcinoma.
Oral oncology, 2017 Oct 22
Outcome by treatment modality in sinonasal undifferentiated carcinoma (SNUC): A case-series, systematic review and meta-analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024 Jul 22
Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial.
Lancet (London, England), 2019-01-12
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.

Related Topics in Medical Oncology

Copyright © 2024 theMednet
All Rights Reserved.